A travoprost intraocular implant (iDose TR; Glaukos) demonstrated a favorable safety profile during the exchange procedure, a 32-subject study showed. The investigators stated that this supports readministration of the implant.

Presenting author Steven R. Sarkisian, MD, and colleagues analyzed data from subjects who were implanted previously with the travoprost implant as part of the phase 2 trial. These subjects were eligible for an exchange (administration of a new implant and removal of their previous implant) and followed for 12 months to monitor for adverse events and perform ophthalmic assessments. Data were presented in a poster at the 2023 annual meeting of the American Academy of Ophthalmology.

The mean time from administration of the first implant in the phase 2 trial to the time of the exchange procedure of the second implant was 4.2 years (overall mean 5.2 years). There were no explantations or endothelial cell loss.